LB Pharmaceuticals (ticker: LBRX) announced on September 15, 2026 that Dr. Susan G. Kozauer has been appointed Chief Medical Officer, effective September 14. Dr. Kozauer, 54, previously led clinical development at Centessa Pharmaceuticals and before that at Intra-Cellular Therapies, bringing substantial trial-stage experience. Her compensation package includes a $515,000 base salary, a target bonus of 40% of base, a $150,000 sign-on bonus with clawback if she leaves within two years, and a 200,000-share stock option vesting over four years.
View Full Filing (SEC EDGAR)